Predicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|6|763-772

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.6, 2018-03, pp. : 763-772

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vedolizumab for ulcerative colitis and Crohn's disease

By  

PRESCRIBER, Vol. 26, Iss. 10, 2015-05 ,pp. : 22-24

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 4, 2015-04 ,pp. : 412-423

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 10, 2015-10 ,pp. : 979-979

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 188-202

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 33, Iss. 1, 2018-02 ,pp. : 21-28

John Wiley & Sons Inc

Access to resources Recommend Favorite